Cibus (CBUS) AI Stock Analysis

• Market Cap: $70.53M
• Dividend Yield: N/A
• Average Volume (3M): 199.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.28
• Revenue Growth: 63.66%
• EPS Growth: 36.72%
• Country: US
• Employees: 157
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.61
• Shares Outstanding: 52,540,527
• 10 Day Avg. Volume: 142,709
• 30 Day Avg. Volume: 199,236
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 3.90
• Enterprise Value/Revenue: 56.80
• Enterprise Value/Gross Profit: 56.80
• Enterprise Value/Ebitda: -1.05
• 1Y Price Target: $20.00
• Price Target Upside: 1438.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 42 Neutral
• Price Target: $1.50 ▲(15.38% Upside)

Cibus's overall stock score is primarily impacted by its weak financial performance and valuation, reflecting ongoing profitability challenges and negative cash flows. Technical indicators suggest bearish momentum, further weighing on the score. While the earnings call provided some positive future guidance, immediate financial and operational challenges remain significant.

Positive Factors

Regulatory Advances

Regulatory acceptance of gene-editing technologies enhances Cibus's ability to market its products globally, supporting long-term growth.

Material Transfer Agreement

This agreement strengthens Cibus's market position in Latin America, enhancing its competitive edge in rice hybrid development.

Revenue Growth Potential

Projected revenue from rice traits indicates strong future cash flow potential, supporting Cibus's financial sustainability.

Negative Factors

Profitability Challenges

Ongoing net losses highlight challenges in achieving profitability, which may affect long-term financial health and investment capacity.

Cash Flow Concerns

Negative cash flow indicates potential liquidity issues, limiting Cibus's ability to invest in growth and manage operational expenses.

EU Regulatory Delays

Delays in EU regulatory processes could hinder Cibus's market expansion and revenue realization in the region.

Cibus Business Overview & Revenue Model

Company Description

Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.

How the Company Makes Money

Cibus generates revenue through the commercialization of its gene-edited agricultural products, which include seeds and crop traits that improve performance and resilience. The company typically licenses its technology to agricultural firms, receiving upfront fees and ongoing royalties based on product sales. Key revenue streams include partnerships with large agricultural companies, which allow Cibus to leverage their distribution networks and market access. Additionally, Cibus may benefit financially from grants and collaborations with research institutions focused on agricultural innovation.

Cibus Financial Statement Overview

Summary

Cibus is experiencing financial difficulties with persistent net losses and negative cash flows. Despite some revenue growth, high debt levels and negative profitability margins indicate a precarious financial position.

Income Statement

Cibus shows a pattern of increasing revenue in the TTM with a 11.5% growth from the previous annual period. However, the company continues to face significant challenges with profitability, as evidenced by a negative EBIT margin and net profit margin. The gross profit margin is positive, but the overall financial health is weakened by substantial net losses.

Balance Sheet

The company's balance sheet indicates a high debt-to-equity ratio, showing a heavy reliance on debt financing. The return on equity remains negative, reflecting ongoing net losses. However, the equity ratio is relatively stable, suggesting some level of balance sheet strength.

Cash Flow

Cibus has a negative free cash flow, which has deteriorated further in the TTM. The operating cash flow to net income ratio is negative, indicating operational challenges in generating cash. While financing activities provide some cash inflow, the continuous negative free cash flow poses a risk to financial sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.85M	4.26M	1.82M	157.00K	25.99M	23.85M
Gross Profit	4.85M	4.26M	1.42M	-1.38M	-2.57M	-11.28M
EBITDA	-262.49M	-241.63M	-314.58M	-15.21M	-25.43M	-41.53M
Net Income	-275.33M	-251.39M	-267.63M	-16.89M	-29.20M	-44.84M
Balance Sheet
Total Assets	346.20M	350.07M	544.41M	22.42M	37.19M	63.33M
Cash, Cash Equivalents and Short-Term Investments	36.46M	14.43M	32.70M	3.43M	13.82M	29.00M
Total Debt	35.42M	36.29M	24.62M	13.54M	17.88M	19.76M
Total Liabilities	271.72M	252.24M	206.12M	15.19M	23.06M	26.45M
Stockholders Equity	72.12M	92.16M	293.47M	7.23M	14.13M	36.88M
Cash Flow
Free Cash Flow	-53.74M	-58.85M	-50.53M	-20.88M	-19.31M	-45.46M
Operating Cash Flow	-52.95M	-58.04M	-46.21M	-19.36M	-18.81M	-43.67M
Investing Cash Flow	-795.00K	-808.00K	55.06M	-1.52M	11.20M	-13.48M
Financing Cash Flow	60.18M	40.60M	20.32M	9.99M	3.74M	15.41M

Cibus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Negative. The current price of 1.3 is below the 20-day moving average (MA) of 1.34, below the 50-day MA of 1.42, and below the 200-day MA of 2.05, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 42.67 is Neutral, neither overbought nor oversold. The STOCH value of 8.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CBUS.

Cibus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVTX	52 Neutral	142.05M	-1.15	-26.41%	―	-45.35%	96.80%
MGX	52 Neutral	85.95M	-0.98	-33.24%	―	-39.62%	6.83%
GANX	46 Neutral	64.35M	-2.72	―	―	―	49.82%
CBUS	42 Neutral	$70.53M	―	-160.72%	―	63.66%	36.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Cibus Corporate Events

Cibus Announces Workforce Reduction Strategy

On July 21, 2025, Cibus, Inc. announced a reduction in workforce by approximately 34 full-time employees as part of its strategy to streamline business operations and focus on its most immediate and funded commercial opportunities. This move is expected to be completed by December 31, 2025, with the company incurring around $0.5 million in one-time charges for accrued vacation and severance payments in the third quarter of 2025, impacting affected employees who were informed on July 23, 2025.

Cibus Announces Public Offering of Common Stock

On June 5, 2025, Cibus, Inc. entered into Securities Purchase Agreements with various investors, including its Board Chairman, as part of a public offering of 15,714,285 shares of Class A Common Stock. The offering, registered with the SEC, aims to raise funds for developing weed management traits in rice and other corporate purposes. The company has placed restrictions on stock transactions for 60 days post-offering. Additionally, Cibus engaged A.G.P./Alliance Global Partners as the sole placement agent, agreeing to a fee structure based on the proceeds from the sale of shares, with certain exclusions for the Board Chairman’s purchases.

Cibus Announces Strategic Realignment to Streamline Operations

Cibus, Inc. announced a strategic realignment to streamline operations, focusing on the commercial advancement of its weed management traits in rice and partner-funded sustainable ingredient programs. The company aims to reduce its annual net cash burn to $30 million by 2026 through cost-cutting measures, including rationalizing human capital and non-core facilities. Recent regulatory approvals in the U.S., Ecuador, and India support the company’s gene editing technologies, potentially enhancing its market positioning and facilitating future partnerships. Cibus plans to launch its rice traits commercially in Latin America by 2027-2028, with further expansion planned in the U.S. and Asia.

Cibus Stockholders Approve 2025 Employee Stock Plan

On May 22, 2025, Cibus, Inc.’s stockholders approved the adoption of the 2025 Employee Stock Purchase Plan (ESPP) during the company’s annual meeting. The plan, which was previously approved by the Board of Directors, includes the reservation of 326,384 shares of Class A common stock, with potential for annual increases. This approval marks a significant step in enhancing employee engagement and investment in the company, potentially impacting Cibus’s market position and stakeholder interests.

Cibus Approves Key Measures at Annual Meeting

On May 22, 2025, Cibus, Inc. held its 2025 Annual Meeting of Stockholders where 64.94% of shares were represented. During the meeting, seven directors were elected, executive compensation was approved, BDO USA, P.C.’s appointment was ratified, and the 2025 Employee Stock Purchase Plan was approved. Additionally, the issuance and repricing of certain warrants, including those held by Rory Riggs, were approved, potentially leading to a change of control under Nasdaq rules.